Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 23, 2026 07:30 ET | Source: Marvel Biosciences Corp.

Marvel Biosciences to Participate and Present at the 2nd Neuroscience Innovation Partnering and Licensing Summit

Marvel Biosciences to participate in 2nd Neuroscience Innovation Partnering & Licensing Summit, allowing Marvel to showcase its progress on global stage
April 07, 2026 07:30 ET | Source: Marvel Biosciences Corp.

Marvel Biosciences Secures Financial and Strategic Investment with 5 Horizon Ventures

Marvel announces financial and strategic backing from 5 Horizons Ventures to support its upcoming Phase 1 clinical trial of patented lead asset MB-204
March 30, 2026 07:30 ET | Source: Marvel Biosciences Corp.

Marvel Biosciences Secures Alberta Innovates Funding to Support the Phase I Testing of MB-204

Marvel Biosciences secures $600,000 in non-dilutive funding from Alberta Innovates to support Phase I clinical trials of its autism-focused patented MB-204
March 27, 2026 16:05 ET | Source: PMGC Holdings Inc.

NorthStrive Biosciences Signs Licensing Agreement Amendment with MOA Life Plus [KOSDAQ: 142760] for Dual Myostatin Assets Targeting Muscle Preservation in Combination with GLP-1 Treatments

NorthStrive Biosciences Signs Licensing Agreement Amendment with MOA Life Plus [KOSDAQ: 142760] for Dual Myostatin Assets Targeting Muscle Preservation in
March 25, 2026 07:30 ET | Source: Marvel Biosciences Corp.

Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204

Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204, lead asset discovery, a patented neuroactive adenosine A2A antagonist
March 12, 2026 10:41 ET | Source: Research and Markets

Pharmaceuticals and Biotechnology Co-promotion and Co-marketing Agreements Trends Report 2026 with Directory of 384 Deal Records - Terms, Structures, and Strategies Behind These Impactful Partnerships

Dublin, March 12, 2026 (GLOBE NEWSWIRE) -- The "Co-promotion and Co-marketing in Pharmaceuticals and Biotechnology 2016-2026" report has been added to ResearchAndMarkets.com's offering. Whether...
March 10, 2026 07:30 ET | Source: PMGC Holdings Inc.

NorthStrive Biosciences Announces Launch of EL-32 Preclinical Study Evaluating Muscle Preservation in GLP-1 Weight Loss Therapy

Northstrive Biosciences Announces Launch of EL-32 Preclinical Study Evaluating Muscle Preservation in GLP-1 Weight Loss Therapy
February 19, 2026 07:30 ET | Source: PMGC Holdings Inc.

NorthStrive Biosciences Files 10 U.S. Patent Applications for EL-22 and EL-32 Targeting Muscle Growth and Yield Enhancement in Farmed Animals

NorthStrive Biosciences Files 10 U.S. Patent Applications for EL-22 and EL-32 Targeting Muscle Growth and Yield Enhancement in Farmed Animals
February 11, 2026 07:30 ET | Source: PMGC Holdings Inc.

NorthStrive Biosciences Signs Definitive License Agreement for Commercialization of EL-22 and EL-32, a Myostatin-Engineered Probiotic for Muscle Preservation in Animal Health

NorthStrive Biosciences Signs Definitive License Agreement for Commercialization of EL-22 and EL-32, a Myostatin-Engineered Probiotic for Muscle Preservati
February 04, 2026 16:30 ET | Source: PMGC Holdings Inc.

NorthStrive Biosciences Announces Progress Updates to Phase III Timeline for AI-Driven Drug Discovery Program with Yuva Biosciences

NorthStrive Biosciences Announces Progress Updates to Phase III Timeline for AI-Driven Drug Discovery Program with Yuva Biosciences